A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Amantadine (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Acronyms ALLAY-LID II
- Sponsors Osmotica Pharmaceutical
- 15 Feb 2018 Status changed from recruiting to discontinued.
- 18 Jun 2016 This trial was Temporarily Halted in Spain.
- 09 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.